Developing Cilastatin
for the treatment
of inflammatory
disorders Cilastatin,
the new
omeprazole
for the kidney.

Homepage-6

es_financiado_por_la_union_europea_rgb_pos
logo_cdti_2023_soportes_digitales (1)
Frame-4
G-M logo
Frame-2
FIB

WHAT IS TELARA PHARMA

Telara Pharma is a global leader in repurposing the drug cilastatin to make new therapies for severe inflammatory disorders like Acute Kidney Injury (AKI).

The scientific team of TELARA has spent years studying toxic and non-toxic aggressions suffered by the kidneys with the aim of preventing and treating AKI. The company arises out of the pioneering work on nephroprotection carried out with cilastatin by the team of the KOL Dr. Alberto Tejedor to cover a medical need that is not currently addressed.

WHAT WE DO WE DO BEST

We are currently advancing cilastatin into phase II clinical trials for the treatment of AKI induced by toxics, sepsis, and sepsis-included acute kidney failure and moving forward proprietary programs to clinical trials to repurpose cilastatin for neuroinflammatory disorders.
Know more about us

About us

telara-pharma-equipo
alberto_tejedor_1

why we do what we do? Telara Pharma

The scientific team of TELARA has spent years studying toxic and non-toxic aggressions suffered by the kidneys with the aim of preventing and treating AKI.

The company arises out of the pioneering work on nephroprotection carried out with cilastatin by the team of the KOL Dr. Alberto Tejedor to cover a medical need that is not currently addressed.

Acute kidney Injury (AKI) is a syndrome that results in a sudden decrease in kidney function and currently is one of the most serious and common health problems in the world associated with severe morbidity and mortality as well as the development of chronic kidney disease (CKD).

Every year, it affects around 13.3 million people, causing 1,7 million deaths. It therefore represents a true epidemic in today’s nephrology where 1 in 5 adults and 1 in 3 children worldwide experience AKI during a hospital episode of care with a mortality rate of 50-80%.

See more about the problem

Cilastatin is a specific competitive blocker of renal dehydropeptidase I (DHP-I) enzyme which is located on brush-border cholesterol rafts of renal tubular cells.

Our preclinical in vitro and in vivo studies have demonstrated that cilastatin protects the kidney against tubular cell injury and acute kidney injury (AKI) caused by nephrotoxic drugs such as cisplatin, cyclosporine and gentamicin, and other non-toxic conditions such as sepsis.

See more about the solution

SCIENTIFIC DATA

If you want to know more, we recommend that you read our Scientific Data section.

Cilastatin is an specific inhibitor of Dipeptidase 1 (DPEP1).

Thanks to the research of the scientific founding team of TELARA the MoA of the nephroprotective effect of cilastatin was elucidated and the cholesterol rafts were stablished as one of the main therapeutic targets of non-necrotic death of the proximal cell...
Read More

Cilastatin blocks the apoptosis process.

Cilastatin specifically protects proximal tubular epithelial cells (PTECs) from death by hindering the internalization of the cholesterol rafts and blocking apoptosis, while it did not offer any type of protection in tumour cell lines of the cervix, breast, colon, bladder...
Read More

Cilastatin avoids the internalization via cholesterol rafts of the Fas/FasL complex preventing the extrinsic pathway of apoptosis.

Therefore, in PTECs, Fas is externalized in these rafts where it trimerizes by its binding to FasL and is internalized, initiating the activation of the extrinsic pathway of apoptosis, caspases, mitochondrial depolarization, cytochrome C translocation and endonuclease activation that will end in cell death...
Read More

Cilastatin is also effective in a non-toxic AKI such as that caused by sepsis.

In the sepsis process AKI is part of a much larger picture (multi-organ failure) with true distant endocrine effects that amplify the initial injury, affecting more organs and systems with lethality rates greater than 90%. ..
Read More

Meet the TEAM

Teresa Tarragó, PhD, MBA​

 Chief Executive Officer

Alberto Lázaro, PhD

Founder & Chief Scientific Officer

Amparo Bravo, PhD, MD

Founder & Chief Medical Officer

Elena Vázquez, PhD

Researcher

Linkedin
Linkedin
Linkedin
Linkedin
Discover our team

Teresa Tarragó, PhD, MBA​

 Chief Executive Officer

Linkedin

Alberto Lázaro, PhD

Founder & Chief Scientific Officer

Linkedin

Amparo Bravo, PhD, MD

Founder & Chief Medical Officer

Linkedin

Elena Vázquez, PhD

Researcher

Linkedin
Discover our team

Check our
PIPELINE

Program  Indication Pre-clinical  Phase I Phase II Phase III Partners
TLP-01 
ACUTE KIDNEY INJURY caused by Drugs
    Licensed to:
TLP-02
ACUTE KIDNEY INJURY caused by Sepsis
      Licensed to:
TLP-03
GLAUCOMA
        wholly-owned
TLP-04
Undisclosed
        wholly-owned
See our pipeline

Need to contact us?

CONTACT

See the latest news